Bio-Techne Competitors

Thermo Fisher Scientific (NYSE:TMO) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

87.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 3.8% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Thermo Fisher Scientific and Bio-Techne's gross revenue, earnings per share and valuation.

Thermo Fisher Scientific has higher revenue and earnings than Bio-Techne. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Thermo Fisher Scientific and Bio-Techne, as provided by MarketBeat.

Thermo Fisher Scientific currently has a consensus target price of $529.6667, indicating a potential upside of 17.68%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, equities research analysts clearly believe Thermo Fisher Scientific is more favorable than Bio-Techne.

Profitability

This table compares Thermo Fisher Scientific and Bio-Techne's net margins, return on equity and return on assets.

Dividends

Thermo Fisher Scientific pays an annual dividend of $0.88 per share and has a dividend yield of 0.2%. Bio-Techne pays an annual dividend of $1.28 per share and has a dividend yield of 0.4%. Thermo Fisher Scientific pays out 7.1% of its earnings in the form of a dividend. Bio-Techne pays out 33.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has raised its dividend for 3 consecutive years and Bio-Techne has raised its dividend for 1 consecutive years.

Volatility and Risk

Thermo Fisher Scientific has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Summary

Thermo Fisher Scientific beats Bio-Techne on 10 of the 17 factors compared between the two stocks.

Illumina (NASDAQ:ILMN) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

90.0% of Illumina shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 0.4% of Illumina shares are owned by insiders. Comparatively, 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Illumina and Bio-Techne's revenue, earnings per share (EPS) and valuation.

Illumina has higher revenue and earnings than Bio-Techne. Illumina is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Illumina and Bio-Techne, as provided by MarketBeat.

Illumina presently has a consensus target price of $365.3158, indicating a potential downside of 16.86%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Bio-Techne's stronger consensus rating and higher possible upside, analysts plainly believe Bio-Techne is more favorable than Illumina.

Profitability

This table compares Illumina and Bio-Techne's net margins, return on equity and return on assets.

Volatility & Risk

Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Summary

Illumina beats Bio-Techne on 8 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Bio-Techne (NASDAQ:TECH) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Institutional and Insider Ownership

93.8% of Bio-Techne shares are held by institutional investors. 3.8% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Agilent Technologies and Bio-Techne's gross revenue, earnings per share and valuation.

Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Agilent Technologies and Bio-Techne, as provided by MarketBeat.

Agilent Technologies presently has a consensus target price of $100.4619, indicating a potential downside of 17.70%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than Agilent Technologies.

Profitability

This table compares Agilent Technologies and Bio-Techne's net margins, return on equity and return on assets.

Dividends

Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. Bio-Techne pays an annual dividend of $1.28 per share and has a dividend yield of 0.4%. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Bio-Techne pays out 33.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 1 consecutive years and Bio-Techne has raised its dividend for 1 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and lower payout ratio.

Risk & Volatility

Agilent Technologies has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Mettler-Toledo International (NYSE:MTD) and Bio-Techne (NASDAQ:TECH) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by insiders. Comparatively, 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Mettler-Toledo International and Bio-Techne's revenue, earnings per share (EPS) and valuation.

Mettler-Toledo International has higher revenue and earnings than Bio-Techne. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Mettler-Toledo International and Bio-Techne, as provided by MarketBeat.

Mettler-Toledo International presently has a consensus target price of $868.0833, indicating a potential downside of 22.22%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Bio-Techne's stronger consensus rating and higher possible upside, analysts plainly believe Bio-Techne is more favorable than Mettler-Toledo International.

Profitability

This table compares Mettler-Toledo International and Bio-Techne's net margins, return on equity and return on assets.

Volatility & Risk

Mettler-Toledo International has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Summary

Bio-Techne beats Mettler-Toledo International on 9 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Volatility & Risk

Bio-Rad Laboratories has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Insider and Institutional Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Bio-Rad Laboratories and Bio-Techne's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Bio-Rad Laboratories and Bio-Techne, as provided by MarketBeat.

Bio-Rad Laboratories presently has a consensus target price of $646.00, indicating a potential upside of 10.52%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 2.60%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, research analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Techne.

Earnings and Valuation

This table compares Bio-Rad Laboratories and Bio-Techne's revenue, earnings per share (EPS) and valuation.

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Bio-Techne (NASDAQ:TECH) and Waters (NYSE:WAT) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Risk & Volatility

Bio-Techne has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.

Institutional and Insider Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 91.8% of Waters shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by company insiders. Comparatively, 1.5% of Waters shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Bio-Techne and Waters' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for Bio-Techne and Waters, as reported by MarketBeat.

Bio-Techne presently has a consensus price target of $352.30, indicating a potential downside of 2.60%. Waters has a consensus price target of $219.4545, indicating a potential downside of 19.87%. Given Bio-Techne's stronger consensus rating and higher possible upside, equities analysts plainly believe Bio-Techne is more favorable than Waters.

Earnings & Valuation

This table compares Bio-Techne and Waters' top-line revenue, earnings per share and valuation.

Waters has higher revenue and earnings than Bio-Techne. Waters is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Techne beats Waters on 10 of the 14 factors compared between the two stocks.